Clinical course of patients with severe COVID-19 pneumonia treated with remdesivir: A real-life study.

Diana TejadaRegina JuanbeltzMaría RiveroRamón San MiguelFerrán CapdevilaJuan José BeloquiMaite Sarobe

Published in: PloS one (2022)

Patients with severe COVID-19 pneumonia and treated with remdesivir require relatively prolonged hospital stays, many with a need for ventilatory support and, in a considerable proportion of cases, admission to the ICU. However, the observed survival rate is high, and the drug is well tolerated.

Keyphrases

coronavirus disease
sars cov
early onset
emergency department
intensive care unit
drug induced
healthcare
adverse drug
respiratory syndrome coronavirus
newly diagnosed
community acquired pneumonia
free survival